Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
IRIDEX (IRIX) Drops 30% After Q3 Revenue Miss and Guidance Reduction

IRIDEX (IRIX) Drops 30% After Q3 Revenue Miss and Guidance Reduction

Key Takeaways

  • Third quarter 2026 revenue declined 19% year over year to $10.2 million, well below consensus estimates of roughly $12.6 million.
  • GAAP net loss was $1.4 million, or $0.08 per share, a wider loss than the approximately $0.04 per share analysts had projected.
  • Gross margin improved sharply to 42.4% from 32.1% a year earlier, driven by favorable geographic mix and pricing discipline.
  • Management lowered full-year 2026 revenue guidance to $46 million–$48 million, down from the prior range of $51 million–$53 million.
  • The shortfall was concentrated in international retina sales and distributor probe-inventory digestion, while the U.S. glaucoma business grew.
  • Shares sold off sharply after the release, reflecting investor disappointment over the guidance cut and top-line miss.

Earnings Context and Why It Matters

IRIDEX Corporation (IRIX), a developer of laser-based medical systems and consumable probes for treating glaucoma and retinal diseases, reported results for the third quarter ended October 3, 2026. This report matters because it tests a multi-year turnaround built on cost discipline and margin improvement. After generating positive adjusted EBITDA and positive operating cash flow in fiscal 2025, the company is pushing toward sustainable profitability. This quarter’s revenue miss and guidance reduction signal that demand headwinds in international markets are offsetting the operational progress management has made, making the path to profitability a central question for investors. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Breaking Down the Reported Results

Total revenue for the third quarter of 2026 was $10.2 million, down 19% from $12.5 million in the prior-year period and below the consensus estimate of roughly $12.6 million. GAAP net loss was $1.4 million, or $0.08 per share, compared with a net loss of $1.6 million, or $0.09 per share, a year earlier.

Within the mix, retina product revenue fell to $5.1 million from $6.7 million, driven primarily by weaker international demand. Revenue from the Cyclo G6 glaucoma product family was $3.2 million versus $3.5 million, as distributors worked through inventory purchased earlier in the year; approximately 11,900 Cyclo G6 probes were sold, down from 14,900 a year ago. The company sold 28 G6 glaucoma laser systems versus 30 in the prior-year quarter.

A bright spot was profitability. Gross margin rose to 42.4% from 32.1% a year earlier, helped by a one-time $0.8 million write-off recorded in the prior-year period, more favorable geographic mix, and sustained pricing discipline. Excluding that prior-year impact, pro forma gross margin was 38.7%, a 370 basis-point improvement. Non-GAAP adjusted EBITDA was a loss of $0.6 million, versus a $0.1 million loss a year ago.

On the balance sheet, cash and cash equivalents stood at $3.7 million as of October 3, 2026, down about $1.0 million from the prior quarter as the company invested in safety-stock inventory tied to its manufacturing relocation to San Jose.

Market Reaction and Investor Sentiment

IRIX shares dropped sharply following the November 17, 2026 release, with the stock falling by roughly 30% in after-hours trading. The reaction reflected two compounding concerns: a top-line miss and a meaningful reduction in full-year guidance. Management attributed the shortfall to softer-than-expected demand in Europe and Asia, distributor inventory digestion ahead of the headquarters relocation, and ongoing regulatory delays, particularly around PASCAL certification in Europe. While the gross-margin improvement was encouraging, investors appeared to weigh the revenue trajectory more heavily, given the company’s limited cash cushion and the recurring nature of its probe-based consumables business.

Forward Outlook and Key Factors to Monitor

Management now expects full-year 2026 revenue of $46 million–$48 million, down from the prior range of $51 million–$53 million, with the guidance continuing to exclude revenue from the Middle East. The company maintained its outlook for adjusted operating expenses of $19 million–$19.5 million.

Looking ahead, management is positioning 2027 as a more profitable year. The completed manufacturing relocation to San Jose is expected to generate roughly $600,000 in annualized rent savings, and the company remains on track to transition major products to third-party contract manufacturers through 2027, a move intended to drive further gross-margin expansion.

Investors should monitor several factors. First, the pace at which safety-stock inventory converts back into revenue and cash, which management expects to support a return toward cash-flow breakeven. Second, the timing of regulatory clearances, including PASCAL MDR certification in Europe, which the company continues to expect in the first half of 2027. Third, whether deferred international orders, including Japan PASCAL shipments, materialize in the fourth quarter. Finally, watch the trajectory of the U.S. glaucoma business, which grew in the quarter and remains the company’s most stable growth engine. From what I see, these elements will be critical in determining whether the company can stabilize and move forward.

Exploring AI Tools for Deeper Analysis

In my view, tools like Tickeron’s AI Screener can be helpful when evaluating companies in the medical technology space. I use it from time to time to filter for comparable names based on fundamentals, technical patterns, and sector trends, which adds context when reviewing earnings like these.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IRIX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


IRIX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 06, 2026

IRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 49 cases where IRIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in 151 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The 10-day RSI Indicator for IRIX moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRIX as a result. In 79 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for IRIX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

IRIX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IRIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for IRIX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.955) is normal, around the industry mean (4.142). P/E Ratio (-3.330) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (3.870) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. IRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -7%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -12%. POAS experienced the highest price growth at 235%, while STIM experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 0%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 10 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of light-based medical systems and delivery devices

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1212 Terra Bella Avenue
Phone
+1 650 940-4700
Employees
108
Web
https://www.iridex.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.